Qvanteq AG

Company founded: January 2009

Novel stent technologies to address and overcome clinical shortcomings.

Qvanteq develops novel stent technologies to address and overcome the clinically adverse effects of today’s available coronary artery stents. A coronary stent is a small (metal) mesh tube which is being implanted into coronary arteries to prevent heart attacks.

Qvanteq is a CTI start-up company and a spin-off from the Swiss Federal Institute of Technology (ETH) Zurich. The company was founded in early 2009 and is held by private investors. Its Headquarter is located at Technopark in Zurich, Switzerland.

Milestones / News

Funding Activity 12.02.2013

Swiss coronary stent developer Qvanteq closes MCHF 4 B round
Funding Activity 27.04.2010

Seed capital round for Qvanteq
Funding Activity 08.09.2009

Qvanteq obtains venture kick first round 10 KCHF

Documents

Qvanteq AG

Arik Zucker

Technoparkstrasse 1
8005 Zürich

http://www.qvanteq.com

Contact

Sharing

Links

Support

Awards (5)

A PHILANTHROPIC INITIATIVE OF A PRIVATE CONSORTIUM

Turning scientific innovation into entrepreneurial activity and job creation is the basis of societal and economical prosperity. In the very early stages, startups bear very high risks that are neither carried by public money nor by private investors. Supporting seed stage startups fills a crucial gap and is therefore purely philanthropic.
Read more about the Foundation of Founders